Abbott India Limited

Equities

ABBOTINDIA

INE358A01014

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:56 19/07/2024 pm IST 5-day change 1st Jan Change
27,408 INR -4.77% Intraday chart for Abbott India Limited -0.27% +19.93%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Abbott India Limited Announces Resignation of Ashok Saini - Commercial Director - GenNext, Vaccines and Neurolife, Effective October 16, 2024 CI
Bain-backed Emcure Pharma's $234 million India IPO draws $11 billion in bids RE
Abbott India Limited Announces Resignation of Sabina Ewing as Director, Effective June 12, 2024 CI
Abbott India's Net Profit Climbs in Fiscal Q4; Shares Up 3% MT
Drugmaker Abbott India posts Q4 profit rise on higher sales RE
Abbott India Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Abbott India Limited Recommends Final Dividend for the Year Ended March 31, 2024, Payable on or After August 13, 2024 CI
Abbott India Limited Appoints Murari Ranganathan as Commercial Director CI
Abbott India's Managing Director Exits MT
Abbott India Limited Announces Resignation of Sandeep Reddy - Commercial Director - Women's Health, Metabolics and International Business, with Effect from June 5, 2024 CI
Abbott India Names Managing Director MT
GSK India arm's Q3 profit falls on government price cap RE
Abbott India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Abbott India Managing Director to Step Down in March 2024 MT
Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
INDIA STOCKS-Indian shares set for muted opening; Delta Corp in focus after tax notice RE
Abbott India warns of laxatives shortage in tussle with Goa regulator RE
Goa state warns Abbott India on antacid license suspension RE
Abbott India Limited Approves Appointment of Sangeeta Shetty as Company Secretary, Effective September 14, 2023 CI
Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Abbott India Limited Appoints Ms Richa Tripathi as Associate Director, Effective August 3, 2023 CI
INDIA STOCKS-Indian shares recover from weak start on buying at key levels RE
Abbott India Limited Approves the Appointment of Sridhar Kadangode as Chief Financial Officer, Effective July 1, 2023 CI
Abbott's India arm posts 9.5% rise in fourth-quarter profit RE
Abbott India's Net Profit Climbs in Fiscal Q4 MT
Chart Abbott India Limited
More charts
Abbott India Limited is an India-based company that is engaged in the pharmaceuticals business. The Company has a portfolio of offerings in diagnostics, medical devices, nutrition products and branded generic medicines. It provides products and solutions across various therapeutic areas, such as women's health, gastroenterology, central nervous system, metabolic, multi-specialty, and vaccines, among others. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Zolfresh (insomnia), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Creon (pancreatic insufficiency), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), Duvadilan (preterm labor), and others. It offers various products under brands, such as Similac, PediaSure, Pedialyte, EleCare, Ensure, Glucerna, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
1st Jan change Capi.
+19.93% 695.69Cr
+47.10% 77TCr
+29.80% 59TCr
-1.31% 37TCr
+15.36% 32TCr
+11.20% 30TCr
+13.82% 25TCr
+14.21% 24TCr
+10.99% 21TCr
+15.02% 18TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBOTINDIA Stock
  4. News Abbott India Limited
  5. Abbott India's Net Profit Climbs in Fiscal Q4